BioNTech's Seoul Data Impresses the Street, but Its CEO Is Selling and Its Cash Cow Is Shrinking
Published on 09/17/2026 at 12:32 | Editorial boerse-global.de
BioNTech finds itself telling two stories at once, and the market is not sure which one to believe. On one side sits a Phase 3 oncology readout from Seoul that has analysts scrambling to lift their price targets. On the other, a founder-CEO quietly offloading stock and a flagship vaccine franchise losing ground faster than expected.
Start with the science, because that is where the clearest numbers live. At the WCLC lung cancer congress in Seoul, BioNTech presented results from the Phase 3 PRESERVE-003 trial of gotistobart, a CTLA-4 antibody developed with partner OncoC4 and also known as BNT316/ONC-392. In patients with advanced squamous non-small cell lung cancer who had already received at least one prior therapy, the drug delivered a median overall survival of 18.5 months. The docetaxel chemotherapy comparator managed just 10 months. Response rates told a similar story: 20% versus 4.8%, with comparable tolerability. The compound already carries FDA fast-track and orphan-drug designations.
A second dataset drew just as much attention. BioNTech's combination of pumitamig and elfetabart, tested in first-line small cell lung cancer, posted a 92% response rate in the first line, 76% in the second, and 52% even among heavily pretreated patients, according to Berenberg. UBS analyst David Dai noted that no dose-limiting toxicities emerged and that the discontinuation rate held at a low 3.9%.
Three Banks, Three Higher Targets
The Street's response was swift and unanimous. Dai reaffirmed his buy rating with a $135 target, pointing to an interim readout expected in 2026 and a possible regulatory filing in 2027. Jefferies analyst Akash Tewari stayed bullish as well, keeping Buy and a $138 target. Berenberg's Harry Gillis went furthest, raising his target from $132 to $140. Gillis's team pegs pumitamig's peak sales potential at $5 billion on a 50% probability of success, with elfetabart adding another $3 billion. The shelved iNeST colorectal cancer vaccine program, once a pillar of the investment case, now matters less to the thesis.
Yet Frankfurt barely flinched. The shares closed Wednesday at EUR 83.60, down 0.2% from the previous day, hovering near their 50-day moving average of EUR 84.21 and roughly 21% below the 52-week high of EUR 105.80 set in January. New York traders reacted more forcefully, pushing the stock higher during US hours — a transatlantic disconnect that hints at how much skepticism still clings to the name.
Should investors sell immediately? Or is it worth buying BioNTech?
The Other Side of the Ledger
That skepticism has a paper trail. On September 8, BMO Capital Markets downgraded the stock from Outperform to Market Perform and cut its price target from $128 to $105. The reasoning was blunt: Comirnaty's revenue is eroding faster than anticipated, de-risking data for pumitamig will not arrive until at least 2028, and expectations for the iNeST program have cooled.
Then there is the insider activity. Between September 8 and 10, CEO Ugur Sahin sold more than 93,000 ordinary shares, executed under a Rule 10b5-1 trading plan established back in June. Such plans exist precisely so that insiders can sell on a schedule without every transaction being read as a verdict on the company's prospects — a legal shield that defuses any suggestion Sahin knows something the market does not.
What the paperwork cannot neutralize is the optics. A founder selling into a stretch of positive pipeline headlines sends no signal of euphoria, even if it sends no signal of panic either. When the person who built the company is not adding to his position while his own science delivers, the question lingers whether management itself expects a near-term re-rating.
A Company in Transition
Weighing both narratives gets you to an uncomfortable middle ground. BioNTech is migrating from vaccine maker to oncology player, and the destination remains years away. The gotistobart data are real and, on the survival front, nearly double the chemotherapy benchmark. But the commercial foundation that made the company a household name is shrinking, and the pipeline's biggest de-risking milestones sit beyond 2028.
The stock's position between its extremes captures the mood: 21% below the January peak of EUR 105.80, yet 23% above the March low of EUR 68.35. With a 30-day annualized volatility of 71%, this is not a name for the faint of heart. Competition is not standing still either — Johnson & Johnson used the same Seoul conference to present new survival data for its RYBREVANT regimen in EGFR-mutated lung cancer, and OncoC4 separately secured FDA fast-track status for another candidate, cesalatamig.
For shareholders, the message from Seoul is that the oncology pipeline is producing hard clinical arguments again after a stretch of muted expectations — arguments that several independent research houses have now chosen to build on. Whether that is enough to carry the full weight of the optimism being priced in is the question Sahin's selling has, fairly or not, made harder to ignore.
Ad
BioNTech Stock: New Analysis - 17 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
